Stimulated Neutrino Transformation with Sinusoidal Density Profiles

Large amplitude oscillations between the states of a quantum system can be stimulated by sinusoidal external potentials with frequencies that are similar to the energy level splitting of the states or a fraction thereof. Situations when the applied frequency is equal to an integer fraction of the energy level splittings are known as parametric resonances. We investigate this effect for neutrinos both analytically and numerically for the case of arbitrary numbers of neutrino flavors. We look for environments where the effect may be observed and find that supernova are the one realistic possibility due to the necessity of both large densities and large amplitude fluctuations. The comparison of numerical and analytic results of neutrino propagation through a model supernova reveals it is possible to predict the locations and strengths of the stimulated transitions that occur.Comment: 14 pages, 6 figure

The neutrino signal at HALO: learning about the primary supernova neutrino fluxes and neutrino properties

Core-collapse supernova neutrinos undergo a variety of phenomena when they travel from the high neutrino density region and large matter densities to the Earth. We perform analytical calculations of the supernova neutrino fluxes including collective effects due to the neutrino-neutrino interactions, the Mikheev-Smirnov-Wolfenstein (MSW) effect due to the neutrino interactions with the background matter and decoherence of the wave packets as they propagate in space. We predict the numbers of one- and two-neutron charged and neutral-current electron-neutrino scattering on lead events. We show that, due to the energy thresholds, the ratios of one- to two-neutron events are sensitive to the pinching parameters of neutrino fluxes at the neutrinosphere, almost independently of the presently unknown neutrino properties. Besides, such events have an interesting sensitivity to the spectral split features that depend upon the presence/absence of energy equipartition among neutrino flavors. Our calculations show that a lead-based observatory like the Helium And Lead Observatory (HALO) has the potential to pin down important characteristics of the neutrino fluxes at the neutrinosphere, and provide us with information on the neutrino transport in the supernova core.Comment: 30 pages, 12 figures, 6 tables, minor correction

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 patients with a chemotherapy-refractory MCRC treated with cetuximab plus chemotherapy were included and clinical response was evaluated according to response evaluation criteria in solid tumours (RECIST). Tumours were screened for KRAS mutations using first direct sequencing, then two sensitive methods based on SNaPshot and PCR-ligase chain reaction (LCR) assays. Clinical response was evaluated according to gene mutations using the Fisher exact test. Times to progression (TTP) were calculated using the Kaplan–Meier method and compared with log-rank test. A KRAS mutation was detected in 22 out of 59 tumours and, in six cases, was missed by sequencing analysis but detected using the SNaPshot and PCR-LCR assays. Remarkably, no KRAS mutation was found in the 12 patients with clinical response. KRAS mutation was associated with disease progression (P=0.0005) and TTP was significantly decreased in mutated KRAS patients (3 vs 5.5 months, P=0.015). Our study confirms that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection

Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial

A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1500 kcal day−1 were included. Chemotherapy, with cisplatin 30 mg m−2 and irinotecan 60 mg m−2, was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44–79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4–72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3–77.3%) and 27.9% (95% CI, 13.4–41.3%), respectively. In conclusion, cisplatin–irinotecan–radiotherapy is an active and well-tolerated regimen feasible in out-patients

Accompagner l’entrée en EHPAD

International audienc

Évaluation et significations de la douleur chez l’adolescent drépanocytaire

International audienc